Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting
04 November 2021 - 7:50AM
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology
company pioneering immuno-neurology, today announced presentations
at the 14th Clinical Trials on Alzheimer's Disease (CTAD)
conference being held November 9-12, 2021 virtually and in Boston,
and the Society for Immunotherapy of Cancer’s (SITC) 36th Annual
Meeting held November 12-14, 2021 virtually and in Washington, D.C.
Among the data being presented at CTAD are twelve-month
biomarker and clinical data from the open-label Phase 2 INFRONT-2
study evaluating AL001 in individuals with frontotemporal dementia
due to progranulin gene mutation (FTD-GRN). Alector will also
present data from its Phase 1 study of AL003 in healthy volunteers
and participants with Alzheimer’s disease. AL003 is being developed
in collaboration with its partner, AbbVie.
At SITC, Alector will provide an update on AL009, a
first-in-class multi-Siglec inhibitor that enhances innate and
adaptive immunity to cancer by blocking a critical glycan
checkpoint pathway.
Alector plans to host a conference call to review these data and
the progress across its pipeline on November 12, 2021, at 4:00 p.m.
ET.
Presentations at CTAD
Oral Presentation:
Presentation Title: Update on
the Phase 2 Study of AL001 in Frontotemporal Dementia Patients
Carrying a Granulin Mutation (OC32)Presenter: Sam
Jackson, M.D., MBA, Alector’s interim Chief Medical
OfficerSession Date
and Time: November 12, 2021 at
1:50 p.m. ET
Poster Presentations:Poster presentations will be available for
on-demand viewing starting November 9, 2021.
Poster Title: A Phase 1 Study of AL003 in
Healthy Volunteers and Participants with Alzheimer’s Disease
(P45)Theme: Clinical trials:
resultsPresenting Author: Michael
Ward, Ph.D., Senior Director, Clinical Science, Alector
Poster Title: A First-in-human
Study of the Anti-Sortilin Antibody AL101
(P46)Theme: Clinical trials:
resultsPresenting Author: Michael
Ward, Ph.D., Senior Director, Clinical Science, Alector
Poster Title: Design of
INFRONT-3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Efficacy and Safety of AL001 IN FTD-GRN
(P71)Theme: New therapies and clinical
trialsPresenting Author: Sam
Jackson, M.D., MBA, interim Chief Medical Officer, Alector
Poster Presentation at SITC
Alector’s poster will be presented on Friday, November 12, 2021,
in the Poster Hall at the Walter E. Washing Convention Center in
Washington D.C.
Poster Title: AL009, a Fusion
Protein and Multi-Siglec Inhibitor, Repolarizes Suppressive Myeloid
Cells and Potentiates Anti-Cancer Effects
(#875)Category: Novel Single-Agent Immunotherapies
Presenting Author: Sam Nalle,
Ph.D., Associate Director, Alector
Conference Call Information
Alector management will host a conference call at 4:00 p.m. ET
on November 12, 2021. Analysts and investors are invited to
participate in the conference call by dialing (888) 705-0365 from
the U.S. and Canada or (415) 817-9241 internationally and using the
conference ID 2065957. The live webcast can be accessed on the
investor page of Alector’s website at investors.alector.com. A
replay of the webcast will be available on Alector’s website
approximately two hours after the completion of the event and will
be archived for up to 30 days.
About AlectorAlector is a
clinical-stage biotechnology company pioneering immuno-neurology, a
novel therapeutic approach for the treatment of neurodegenerative
diseases. Immuno-neurology targets immune dysfunction as a root
cause of multiple pathologies that are drivers of degenerative
brain disorders. Alector has discovered and is developing a broad
portfolio of innate immune system programs, designed to
functionally repair genetic mutations that cause dysfunction of the
brain’s immune system and enable the rejuvenated immune cells to
counteract emerging brain pathologies. Alector’s immuno-neurology
product candidates are supported by biomarkers and target
genetically defined patient populations in frontotemporal dementia
and Alzheimer’s disease. This scientific approach is also the basis
for the company’s immuno-oncology programs. Alector is
headquartered in South San Francisco, California. For additional
information, please visit www.alector.com.
Alector ContactsMichelle CorralVP,
Communications and Investor
Relations650-808-7016michelle.corral@alector.com
1AB (media)Dan Budwick973-271-6085dan@1abmedia.com
Argot Partners (investors)Laura Perry/Eric KasperArgot
Partners212.600.1902alector@argotpartners.com
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alector (NASDAQ:ALEC)
Historical Stock Chart
From Apr 2023 to Apr 2024